Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 1997

View Archived Issues

Company Profile: Coulter

Cambridge NeuroScience: Q3 1997 highlights

Teva receives FDA approval for generic etodolac

Genentech: Q3 1997 highlights

Ansan and Discovery Laboratories merge

Genetronics and Abbott enter drug supply alliance

Ibex announces changes in product development schedule

Axis receives grant for plant-based vaccine development; phase I trials to begin in 1999

Triangle Pharmaceuticals: Q3 1997 highlights

rhIL-10 improves quality of life in patients with Crohn's disease

AHP describes new compounds with tissue-selective estrogenic and antiestrogenic effects

Novel retinoids from Roche

New antiasthma compound reported at Japanese congress

Bayer focuses on agents for atherosclerosis

Esteve presents new calcium antagonists with potential as neuroprotectants

New melanogenesis inhibitor isolated from actinomycete

BE-32030B: new antitumor agent produced by Nocardia

Preclinical results reported for Novartis' PDE IV inhibitor

Pharmacological profile and antihypertensive effects of YM-358

Dual-action compound YM-158 shows potential for asthma

Effects of AE-0047 on cerebral ischemia/edema and renal injury

AVID study results reported

Gynecare merges with Johnson & Johnson

New anesthetic agent in phase I at Synthelabo

IL-2 gene therapy for metastatic solid tumors: phase I results

FDA approves Gensia Laboratories' generic bumetanide injection

Phase I/II clinical trial of gene therapy for melanoma

U.S. patent covers new melanoma antigen/MAb discovered by Cytoclonal

Biomira withdraws NDS for Tru-Scint imaging kit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...